tbuckley/cabot-search huggingface dataset:
A quarter century of chemotherapy
Authors: G. H. Hitchings
Journal: JAMA (1969)

A Passano Award, quite as much as John Donne's tolling bell, marks a time in which to pause and to reflect on the interdependence of humankind and of scientists and of scientific progress in particular. I wonder how many of you can recall the state of chemotherapy 30 years ago? At that time sulfanilamide was hailed as the "drug of the year" by Dr. Morris Fishbein, then editor ofThe Journal. As quoted by the<i>Boston Herald</i>on Dec 31, 1939, he said, "By repeated success, sulfanilamide established itself as one of medicine's few specifics, those remedies which are especially suited to cure certain diseases. The list includes quinine for malaria, arsphenine for syphilis, and diphtheria antitoxin." Sulfanilamide made four. Period. What I wish to discuss, however, is not the encouragement which that discovery gave to the search for specific remedies, but rather the conceptual advances that it stimulated. As
Scarlatina in Utero.
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Do bad outcomes mean substandard care?
Authors: S. A. Schroeder
Journal: JAMA (1991)

In the study by Caplan et al<sup>1</sup>in this issue, a partial explanation of a persistent conundrum is offered. Previous research has shown that patients with serious adverse events are likely to be judged as receiving inappropriate or negligent care.<sup>2,3</sup>For example, in the recently published Harvard Medical Practice Study,<sup>3</sup>negligence was identified in 51% of adverse events that resulted in death but in only 22% of events that led to minimal impairment. Was the care really poor, or did the bad outcomes influence the review process? This study suggests that the reviewer's knowledge of the outcomes of care clouds the assessment of the process. Physician reviewers were presented with anesthesia cases from closed claims files and asked to review them for appropriateness of care using implicit criteria. Two versions of the same case were offered, identical in every respect except for the seriousness of the outcome.
The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations
Authors: Akshay K. Vaishnaw, Jason R. Orlinick, Jia-Li Chu, Peter H. Krammer, Moses V. Chao, Keith B. Elkon
Journal: Journal of Clinical Investigation (1999)

Figure 4 Defective protein-protein interactions of ICD CD95 mutant alleles.(a) ICD CD95 mutant alleles fail to recruit FADD to the CD95 death domain.293T cells were cotransfected with pCDNA3 expression vectors for WT or mutant CD95 and Flag-FADD in pFlag-CMV-2.Transfected cells were lysed and subjected to IP-Western blot using the antibodies indicated in the figure.The trace signals of WT CD95 in lanes P1, P5, and P10 are due to slight spillover from adjacent lanes and were not seen when these mutants were run separately.(b) The dominant-negative action of ICD mutant CD95 is dose-dependent.293T cells were transiently cotransfected with expression vectors for Flag-FADD and WT or P10 mutant CD95.Transfections were carried out using constant amounts of total DNA (4 μg) using the pCDNA vector DNA, WT CD95 (0.5 μg) and Flag-FADD (0.5 μg) DNA, but the amount of DNA for the ICD mutant P10, was increased between experiments (lanes 4-6; + [0.5 μg] to +++ [1.5 μg]).The total amount of DNA transfected was kept constant.Transfected cells were lysed and analyzed by immunoprecipitation followed by Western blotting using the antibodies indicated.IP, immunoprecipitation.
Incidence of Milk Sensitivity and Development of Allergy in Infants
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Incorrect Data in Table.
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Regulation of Hemoglobin Synthesis during the Development of the Red Cell
Authors: Arthur W. Nienhuis, Edward J. Benz
Journal: New England Journal of Medicine (1977)

Erythroid Progenitor CellsThe cellular phenomena that occur during the early phases of erythropoiesis involve commitment of progenitor cells to the erythroid pathway and subsequently to the expression of certain individual globin genes. Elucidation of the properties of these cells must precede analysis of the molecular basis of these commitment events.Colony-Forming Unit–ErythroidA means to gain important insights into the mechanism of erythroid differentiation has been provided by the ability to assay erythroid progenitor cells in vitro.353 354 355 356 357 358 359 360 Small colonies containing 8 to 64 nucleated red cells were initially observed in cultures of mouse hematopoietic tissue . . .
Selected Writings of Sir Arthur Hurst (1879-1944).
Journal: Annals of Internal Medicine (1972)

bers of the Society).Hurst was probably the most original thinker of his contemporary physicians.Indomitable in the face of deafness and chronic asthma he was an iconoclast, destroy- ing long-held beliefs based on flimsy foundations.Thus his work on radiography of the alimentary tract exploded the fiction of various intra-abdominal ptoses as being capable of causing symptoms, and his contributions leading up to 'The Sins and Sorrows of the Colon', arrested the widespread and harmful indulgence in purgatives.The still more noxious belief in intestinal toxaemia, which led to colectomy for condi- tions ranging from thyrotoxicosis to backache, he likewise demonstrated as a myth.His brilliant and versatile mind did not, however, include the power of critical appraisal of his sometimes hastily conceived theories.Recurrence of carcinoma in the remnant of the stomach he persistently asserted was a redevelopment of the disease arising from residual gastritis.His ingrained suspicion of surgery gave him an unduly optimistic view of the treatment of ulcerative colitis with anti-dysenteric serum, and of duodenal ulcer with medical care.He would not have been at home in the present climate of double-blind trials and statisticians.Dr. Hunt has succeeded remarkably in presenting a picture of Hurst by the pains- taking selection of some 41 papers from 250 contributions, many in French and German, written from 1901 to 1944.The war neuroses, radiography and the colon will probably be regarded as the most permanent of a series of outstanding achieve- ments.From those of us who knew and admired Hurst, and from all gastroenterologists a debt of gratitude is due to Dr. Hunt for a labour of love so efficiently completed.
Blindness in Saudi Arabia
Authors: A. Sommer
Journal: JAMA (1986)

Depending on definitions and how you count, an estimated 42 million people are blind. Over 80% reside in developing countries, where blindness rates are often five to 20 times those of wealthier industrialized nations.<sup>1,2</sup>The majority of Third World blindness is caused by cataract<sup>3,4</sup>; the rest, depending upon local conditions, by trachoma,<sup>5</sup>onchocerciasis (river blindness),<sup>6</sup>malnutrition (xerophthalmia),<sup>7,8</sup>trauma, and glaucoma.<sup>2,3</sup>It is concentrated in the elderly, particularly women. Most importantly, it can be prevented or reversed with existing technology. In a carefully conducted nationwide prevalence survey reported in this issue, Tabbara and Ross-Degnan<sup>9</sup>document the magnitude and causes of blindness in Saudi Arabia, confirming findings of similar surveys in Nepal<sup>10</sup>and Malawi<sup>11</sup>and more modest investigations elsewhere. These have revealed the unacceptable burden of this avoidable disability, with its economic and human costs, and enabled governments with severely limited resources to
Environmental Genotoxicity Evaluation Using Cytogenetic End Points in Wild Rodents
Authors: Angela Maria de Souza Bueno, Carlos Alberto de Bragança Pereira, M. Nazareth Rabello-Gay
Journal: Environmental Health Perspectives (2000)

We analyzed cytogenetic end points in three populations of two species of wild rodents--Akodon montensis and Oryzomys nigripes--living in an industrial, an agricultural, and a preservation area at the Itajaí Valley, state of Santa Catarina, Brazil. Our purpose was to evaluate the performance of the following end points in the establishment of a genotoxic profile of each area: the polychromatic/normochromatic cell ratio; the mitotic index; the frequency of micronucleated cells both in the bone marrow and peripheral blood; and the frequency of cells with chromosome aberrations in the bone marrow. Preparations were obtained using conventional cytogenetic techniques. The results showed a) the role of the end points used as biomarkers in the early detection of genotoxic agents and in the identification of species and populations at higher risk; b) the difference in sensitivity of the species selected as bioindicators in relation to the cytogenetic end points analyzed; c) the need to use at least two sympatric species to detect the presence of genotoxins in each locality; and d) the need to use several end points when trying to establish a genotoxic profile of an area.
X-Linked Ichthyosis and Ichthyosis Vulgaris
Authors: Robert S. Wells
Journal: JAMA (1967)

From hospital records and referral by dermatologists 204 persons were ascertained through 75 probands who had inherited ichthyosis either as an autosomal dominant or as an X-linked recessive trait. Clinical examination of 148 of these patients confirmed previously recorded differences between the two varieties. Further features are described which may enable the sporadic case to be properly classified. Histological differences were also confirmed. In the X-linked families an effect of the gene was marked in one of the many heterozygous females. The Xg groups of the families finally established measurable distance between the locus for this X-linked blood group system and the locus for the X-linked form of ichthyosis, a linkage which had already seemed probable from studies of a series of families in Oxford, England, and Tel-Hashomer, Israel.
Mediation of Cytotoxic Immune Responses Against Human Tumor-Associated Antigens by Allogeneic Immune RNA2
Authors: David H. Kern, Dieter Fritze, Peter M. Schick, Nancy Chow, Yosef H. Pilch
Journal: JNCI Journal of the National Cancer Institute (1976)

Allogeneic immune RNA (I-RNA), extracted from the peripheral blood lymphocytes of patients putatively cured of cancer, mediated cytotoxic immune reactions that apparently were directed specifically against human tumor-associated antigens. I-RNA was extracted from the peripheral blood lymphocytes of patients with various types of cancer. Patients selected had not been previously sensitized to HL-A or other normal transplantation antigens or to blood group antigens. Normal human peripheral blood lymphocytes were incubated with these allogeneic I-RNA preparations and tested for cytotoxicity against human target cells in vitro. Allogeneic I-RNA mediated cytotoxic immune reactions only against tumor target cells of the same histologic type as the I-RNA donor. I-RNA's extracted from peripheral blood lymphocytes of melanoma patients mediated cytotoxic immune reactions only against melanoma cells. Similarly, only I-RNA's extracted from the lymphocytes of patients with colon cancer mediated cytotoxic immune reactions against colon carcinoma cells, and only I-RNA's from the lymphocytes of breast cancer patients mediated immune reactions against breast cancer target cells. Allogeneic I-RNA extracted from peripheral blood lymphocytes of cancer patients possibly mediated specific cytotoxic immune reactions that were directed against common tumor-associated antigens shared by human tumors of similar histologic type.
Publisher Correction: BRD4 interacts with NIPBL and BRD4 is mutated in a Cornelia de Lange–like syndrome
Authors: Gabrielle Olley, Morad Ansari, Hemant Bengani, Graeme R. Grimes, James Rhodes, Alex von Kriegsheim, Ana Blatnik, Fiona J. Stewart, Emma Wakeling, Nicola Carroll, Alison Ross, Soo-Mi Park, Wendy A. Bickmore, Madapura M. Pradeepa, David R. FitzPatrick
Journal: Nature Genetics (2018)
Our Priorities
Authors: Gerald D. Dorman
Journal: JAMA (1969)

I assume this office today with the realization that my voice is to speak for the American medical profession. This in itself is a humbling fact. It is my desire to reflect the sentiments of the majority of active, practicing physicians of this nation. As in any democratic institution, we hold diverse opinions among the 221,000 active members of the AMA. Nevertheless, there is a unanimity amongst us in our determination to bring the best possible care to the people who need it, to the people of the United States, our patients. This is our main objective. Seated on this platform are the presidents of our 54 state and territorial associations and the presidents of our specialty societies dedicated to this high professional aim. Also with us today are presidents and representatives of 26 foreign nations who have come from every continent on this earth to join with us on
Abstract 1523: Inhibition of SUMOylation by TAK-981 induces antitumor innate immune responses by modulating macrophage and NK cell function through Type I IFN pathway activation
Authors: Akito Nakamura, Stephen Grossman, Keli Song, Neeraja Idamakanti, Gary Shapiro, Dennis Huszar
Journal: Cancer Research (2019)

Abstract TAK-981 is a novel and selective small molecule inhibitor of the small ubiquitin-like modifier (SUMO) ylation enzymatic cascade in Phase 1 clinical trials. SUMOylation is a reversible post-translational modification that regulates protein function by covalent attachment of a SUMO protein to protein substrates. We have found that in vivo inhibition with TAK-981 promotes an antitumor immune response characterized by induction of a Type I interferon (IFN) response in immune cells. Interestingly, others have also reported a role for SUMOylation in restraining Type I IFN responses, upon exposure to pathogenic stimuli, using genetic approaches to inhibit SUMOylation. In this study, we demonstrate that inhibition of SUMOylation with TAK-981 enhances antitumor innate immunity by modulating macrophage and NK cell function. In vitro studies revealed that TAK-981 treatment increased expression of pro-inflammatory markers and prevented expression of anti-inflammatory markers on macrophages. TAK-981 treatment of macrophages further resulted in potent phagocytic activity against cancer cells. TAK-981 also induced expression of activation markers on NK cells and enhanced cell killing activity against cancer cells. Enhancement of macrophage phagocytosis and NK cell cytotoxicity by TAK-981 were shown to be dependent on Type I IFN receptor signaling, and both activities against CD20-positive cancer cells were further enhanced in the presence of the anti-CD20 therapeutic monoclonal antibody rituximab. Evaluation of combination activity in vivo in CD20-positive lymphoma xenograft models demonstrated synergistic antitumor activity in multiple models when TAK-981 was combined with rituximab. Inhibiting SUMOylation with TAK-981 appears to represent a novel and mechanistically unique means to the end of leveraging the potential of Type I IFNs to promote antitumor immune responses. Citation Format: Akito Nakamura, Stephen Grossman, Keli Song, Neeraja Idamakanti, Gary Shapiro, Dennis Huszar. Inhibition of SUMOylation by TAK-981 induces antitumor innate immune responses by modulating macrophage and NK cell function through Type I IFN pathway activation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1523.
Endonexin II, present on human liver plasma membranes, is a specific binding protein of small hepatitis B virus (HBV) envelope protein Hertogs K, Leenders WPJ, Depla E, DeBruin, WCC, Meheus L, Raymackers J, Moshage H, Yap SH. Virology 1993:549–557
Journal: Hepatology (1994)
DEATHS OF THE YEAR.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
OUR NATIONAL BIRTHDAY, PAST AND PRESENT
Journal: JAMA (2012)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
British Medical Journal, London
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal